A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes

Cancer Research

Volumn 60, Issue 22, 2000, Pages 6272-6275

  Schultz, Erwin S ^a   Lethé, Bernard ^a   Cambiaso, César L ^b   Van Snick, Jacques ^a   Chaux, Pascal ^a   Corthals, Jurgen ^c   Heirman, Carlo ^c   Thielemans, Kris ^c   Boon, Thierry ^a   Van der Bruggen, Pierre ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; SKIN METASTASIS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BACULOVIRIDAE; CD4-POSITIVE T-LYMPHOCYTES; CLONE CELLS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI; HLA-DP ANTIGENS; HUMANS; MELANOMA; NEOPLASM PROTEINS; SPODOPTERA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033693387     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: Requirement for tumor helper peptides in priming for skin test reactivity to a P815AB-related peptide
2. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
3. Human tumor antigens: Implications for cancer vaccine development
4. Structure, chromosomal localization and expression of twelve genes of the MAGE family
5. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes
6. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DRl 1
7. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma
8. A MAGE-A4 peptide presented by HLA-A 2 is recognized by cytolytic T lymphocytes
9. A simplified system for generating recombinant adenoviruses
10. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins
11. Proteolysis in MHC class II antigen presentation. Who's in charge?
12. The role of endosomes and lysosomes in MHC class II functioning
13. Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule
14. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
15. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses
16. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells
17. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
18. Vaccination with MAGE-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
19. + T cell responses in antitumor immunity
20. CD4 T cells and their role in antitumor immune responses
21. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
22. The central role of CD4+ T cells in the antitumor immune response
23. - T cells. Tumor eradication does not require participation of cytotoxic T cells
24. + T cells
25. Reactivity of autologous CD4+ T lymphocytes against human melanoma
26. Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell
27. Phenotypic analysis of antigen-specific T lymphocytes